Essential blepharospasm is an idiopathic focal dystonia that consists of involuntary closure of the eyelids and eyebrow region that may render the inflicted patients functionally blind.'5 It usually starts with increased frequency of blinking and may progress to involuntary prolonged muscular contractions.
Oromandibular dystonia or Meige syndrome consists of involuntary contractures of the muscles around the mouth innervated by the other nerves especially the fifth, tenth, and twelfth cranial nerves in association with blepharospasm. Meige syndrome was described by Andre Meige, the French neurologist in 1910. Eyelid involvement may predate or follow midfacial, oral, mandibular, laryngeal, or pharyngeal involvement. Associated involuntary movements include facial grimacing, frowning, head titubation, torticollis, and spastic dysphonia. Essential blepharospasm, Meige syndrome, and spasmodic torticollis are dystonic movement disorders or dyskinesias that typically present in the fifth and sixth decades of life."°B otulinum toxin, type A, blocks the release of the neurotransmitter acetylcholine at the muscle end plate and is currently the treatment of choice for benign essential blepharospasm and Meige syndrome.
We previously reviewed 50 patients initially treated with botulinum toxin injections between September 1983 and June 1984 and followed for 7 years. The study included 34 patients with blepharospasm, 13 with hemifacial spasm, and four with Meige syndrome.'0 Of the original 50 patients, 26 (52%) continued to return for periodic injections and included 18 of 33 patients with blepharospasm, seven of 13 with hemifacial spasm, and one of four with Meige syndrome.'0 A long term study of a large cohort of patients with benign essential blepharospasm and Meige syndrome and their treatment selections has not been reported.'-'°We, therefore, analysed 239 patients who were examined and treated for 11 years in order to determine: (1) whether botulinum toxin injections are accepted by patients on a long term basis, and (2) the role of other treatment modalities including oral medications and surgery in controlling facial contractures. Midfacial and mandibular spasms were treated with a total of 5 units injected in two separate locations in the upper face in the area of the malar eminence and just medial to the mid aspect of the inferior orbital rim. In patients with spasms of the jaw, 5 units were given at the angle of the jaw in the muscle just above the condyle of the jaw (below the zygomatic arch) but not into the joint space. Doses of 5-7.5 units were given in two to three sites along the ramus of the jaw. Injections adjacent to the corner of the mouth were avoided because of the possibility of induced drooling, asymmetric smile, or inadvertent biting of a flaccid buccal mucosa.
Materials and methods
Two weeks after injection, the effects of the treatment were assessed on subjective and objective criteria. The percentage of 'overall improvement' was subjectively determined by each patient and compared with pretreatment. The relative weakness of the eyelids on forced closure was graded objectively by the examiner on a scale from +1 to +4 (+1 is the least amount of force generated). Evidence of residual spasm was also evaluated by the examiner. Patients with a 75-80% improvement who were subjectively 'satisfied' with improvement in performing daily functions and who had minimal objective evidence of residual spasm were asked to return only when the spasm recurred to almost pretreatment intensity.
Patients not satisfied with their result and with residual eyebrow and/or upper eyelid spasms received injections above the medial eyebrows (5 units in two sites above the medial aspect of the brow). Additional drug was given in the upper lid (5 units in each lid) unless ptosis or superior rectus weakness was present. Patients with residual facial contractures were re-examined in 2 weeks (4 weeks after the initial injection). At this time, eyelid injections (5 units additionally in each upper lid) were repeated at 2 week intervals until a therapeutic effect was achieved. The cumulative dose of the previous week's injections was given on re-injection several months later after the successful dose was established. For example, if repeat upper eyelid injections were necessary 2 weeks after the initial injection, a total of 10 units (rather than 5 units) was given in each upper eyelid on re-injection (since 5 units were given in each eyelid on the first injection and 5 units were injected 2 weeks later).
In general, patients were asked to return for another treatment session when the effects of the drug were sufficiently dissipated that involuntary eyelid and facial spasms were almost at the pretreatment level. The following data were obtained from the chart review: diagnosis, duration of disease before treatment with botulinum toxin, type A, median number of injections and median duration of effect, and other treatments including oral pharmacological agents and surgery, and complications. Patients no longer followed were interviewed by telephone.
All patients with a satisfactory response to botulinum toxin, who were previously prescribed oral pharmacological agents, were asked to consult the prescribing physician in order to stop such medications. In addition, patients with an unsatisfactory response to injections were asked to consult their primary care physician to consider administration of an oral agent to possibly enhance or replace the botulinum treatment.
Results
In all, 239 patients included in the study were examined or treated with botulinum toxin, type A, injections over an 11 year period. A total of 222 patients had benign essential blepharospasm (84 males and 138 females) and 17 patients had Meige syndrome (four males and 13 females); 228 patients were treated with botulinum toxin.
The mean duration of action was 14.9 weeks for 211 patients with blepharospasm and 11 weeks for the 17 patients with Meige syndrome. Not all patients were followed for 11 years. The patients received the injections at expected timely intervals and there was no evidence of tolerance to the drug. Patients never treated Eleven patients with blepharospasm were seen in consultation but for a variety of reasons were never treated with botulinum toxin and chose other treatment methods (Table 2) .
One patient sought relief from psychotherapy and enjoyed significant improvement in the blepharospasm for more than 3 years after cessation of all treatment. Another patient was treated for 4 years with oral benzhexol.
SURGERY AS ADJUNCTIVE TREATMENT TO BOTULINUM TOXIN INJECTIONS
Seven patients had blepharoplasty surgery which was combined with levator aponeurotic reinsertion (two patients) and limited upper eyelid orbicularis myectomy (two patients). These additional seven patients continued to receive botulinum toxin injections at expected intervals with no increased duration per injection but with a subjective improvement compared with presurgical effectiveness of the injections.
ORAL PHARMACOLOGICAL AGENTS AS ADJUNCTIVE TREATMENT TO BOTULINUM TOXIN INJECTIONS
In addition to botulinum toxin, 99 patients opted for oral pharmacological treatment from their family physician or neurologist ( Other treatments, to the exclusion of botulinum toxin injections, included radical orbicularis myectomy surgery (three patients), psychotherapy (one patient), and oral anticholinergic medication (one patient). Such modalities were ultimately chosen as the primary treatment by a small minority of the 239 patients in this series.
Adjunctive treatments to the botulinum toxin injections included eyelid surgery and oral anxiolytic medications. Six patients underwent excision of excess skin and plication of the levator aponeurosis. Drug therapy was prescribed by the primary care physician or neurologists for 99 patients. Most patients obtained additional relief from anxiolytic medications (51 patients). These data strongly suggest that while botulinum toxin helps to control the symptoms of blepharospasm and Meige syndrome, limited myectomy and pharmacological agents may enhance the effectiveness of the injections. Since antianxiety medications are the most common drugs taken along with botulinum, control of stress by any technique may similarly augment the effects of botulinum toxin.
We conclude that botulinum A toxin is a well tolerated long term treatment of blepharospasm. The greatest management problem lies in patients who do not respond to the drug. 
